Raiffeisen Bank International AG boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 38.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,831 shares of the biopharmaceutical company's stock after buying an additional 14,937 shares during the quarter. Raiffeisen Bank International AG's holdings in Pfizer were worth $1,357,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of PFE. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. Round Hill Asset Management boosted its stake in shares of Pfizer by 8.2% during the fourth quarter. Round Hill Asset Management now owns 152,162 shares of the biopharmaceutical company's stock valued at $4,037,000 after purchasing an additional 11,514 shares in the last quarter. Wellspring Financial Advisors LLC boosted its stake in shares of Pfizer by 49.9% during the fourth quarter. Wellspring Financial Advisors LLC now owns 16,693 shares of the biopharmaceutical company's stock valued at $443,000 after purchasing an additional 5,560 shares in the last quarter. Finally, Certior Financial Group LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $421,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Trading Up 0.3%
Shares of PFE stock opened at $23.56 on Tuesday. The stock has a market capitalization of $133.95 billion, a PE ratio of 17.07, a P/E/G ratio of 0.85 and a beta of 0.52. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The business has a 50-day moving average of $24.37 and a 200 day moving average of $24.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio (DPR) is 124.64%.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on PFE shares. TD Cowen cut their price target on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. BMO Capital Markets cut their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.
View Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.